Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer.

Nadkarni NJ, Geest KD, Neff T, Young BD, Bender DP, Ahmed A, Smith BJ, Button A, Goodheart MJ.

Cancer Lett. 2013 Apr 30;331(1):99-104. doi: 10.1016/j.canlet.2012.12.016. Epub 2012 Dec 23.

PMID:
23268330
2.

[Prognostic value of microvessel density and angiogenesis-related molecules in epithelial ovarian cancer].

Tan XJ, Lang JH, Lou WZ, Shen K, Xu XY.

Zhonghua Zhong Liu Za Zhi. 2008 Apr;30(4):274-8. Chinese.

PMID:
18788631
3.

Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival.

Pieretti M, Hopenhayn-Rich C, Khattar NH, Cao Y, Huang B, Tucker TC.

Cancer Invest. 2002;20(1):11-23.

PMID:
11852993
4.

Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.

Beltrame L, Di Marino M, Fruscio R, Calura E, Chapman B, Clivio L, Sina F, Mele C, Iatropoulos P, Grassi T, Fotia V, Romualdi C, Martini P, Noris M, Paracchini L, Craparotta I, Petrillo M, Milani R, Perego P, Ravaggi A, Zambelli A, Ronchetti E, D'Incalci M, Marchini S.

Ann Oncol. 2015 Jul;26(7):1363-71. doi: 10.1093/annonc/mdv164. Epub 2015 Apr 6.

PMID:
25846551
5.

Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.

Skírnisdóttir I, Seidal T.

Int J Gynecol Cancer. 2011 Aug;21(6):1024-31. doi: 10.1097/IGC.0b013e31821dc906.

PMID:
21792012
6.

Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.

Nielsen JS, Jakobsen E, Hølund B, Bertelsen K, Jakobsen A.

Int J Gynecol Cancer. 2004 Nov-Dec;14(6):1086-96.

PMID:
15571614
7.

Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?

Reitsma W, de Bock GH, Oosterwijk JC, ten Hoor KA, Hollema H, Mourits MJ.

Int J Gynecol Cancer. 2012 May;22(4):579-85. doi: 10.1097/IGC.0b013e31823d1b5c.

PMID:
22274543
8.

Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.

Gadducci A, Cosio S, Zola P, Sostegni B, Fuso L, Sartori E.

Int J Gynecol Cancer. 2013 Mar;23(3):461-8. doi: 10.1097/IGC.0b013e318286665b.

PMID:
23370604
9.

MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.

Lee H, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE, Swisher E, Kiviat NB, Feng Q.

World J Surg Oncol. 2012 Aug 27;10:174.

10.
11.

Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.

Risum S, Loft A, Engelholm SA, Høgdall E, Berthelsen AK, Nedergaard L, Lundvall L, Høgdall C.

Int J Gynecol Cancer. 2012 Sep;22(7):1163-9.

PMID:
22810969
12.

p53 mutation is infrequent in clear cell carcinoma of the ovary.

Ho ES, Lai CR, Hsieh YT, Chen JT, Lin AJ, Hung MH, Liu FS.

Gynecol Oncol. 2001 Feb;80(2):189-93.

PMID:
11161858
13.

A detailed study of patients and tumor characteristics of epithelial ovarian cancer in Saudi women.

Al-Badawi IA, Munkarah AR, Tulbah A, Babic II, Al Husaini H, Ahmad S.

Int J Gynecol Cancer. 2013 Mar;23(3):456-60. doi: 10.1097/IGC.0b013e318284aafe.

PMID:
23360812
14.

Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?

Rocconi RP, Sullivan P, Long B, Blaize M, Brown J, Arbuckle J, Bevis K, Estes JM, Reed E, Finan MA.

Int J Gynecol Cancer. 2012 Jun;22(5):786-91. doi: 10.1097/IGC.0b013e31825104f4.

PMID:
22552832
15.

RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.

Sanada S, Futami K, Terada A, Yonemoto K, Ogasawara S, Akiba J, Yasumoto M, Sumi A, Ushijima K, Kamura T, Furuichi Y, Yano H.

PLoS One. 2013 Aug 9;8(8):e72820. doi: 10.1371/journal.pone.0072820. eCollection 2013.

16.

p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.

Laframboise S, Chapman W, McLaughlin J, Andrulis IL.

Cancer J. 2000 Sep-Oct;6(5):302-8.

PMID:
11079169
17.

The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.

Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR, Buller RE.

Clin Cancer Res. 2005 May 15;11(10):3733-42.

18.

Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.

Fotopoulou C, Zang R, Gultekin M, Cibula D, Ayhan A, Liu D, Richter R, Braicu I, Mahner S, Harter P, Trillsch F, Kumar S, Peiretti M, Dowdy SC, Maggioni A, Trope C, Sehouli J.

Ann Surg Oncol. 2013 Apr;20(4):1348-54. doi: 10.1245/s10434-012-2673-z. Epub 2012 Oct 2.

PMID:
23054114
19.

Kallikrein-related peptidase 10 (KLK10) expression and single nucleotide polymorphisms in ovarian cancer survival.

Batra J, Tan OL, O'Mara T, Zammit R, Nagle CM, Clements JA, Kedda MA, Spurdle AB.

Int J Gynecol Cancer. 2010 May;20(4):529-36. doi: 10.1111/IGC.0b013e3181d9273e.

PMID:
20686372
20.

Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.

Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R.

Clin Cancer Res. 2005 Dec 1;11(23):8372-83.

Supplemental Content

Support Center